Vital Therapies Outlines Plans for New Phase 3 Trial of ELAD(R) in Alcohol-Induced Liver Decompensation
September 28, 2015 07:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Workforce and Cost Reduction Plans to Conserve Capital for a Possible New Clinical Trial
September 03, 2015 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Additional Data From VTI-208 Presented at Rostock Conference
August 31, 2015 08:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 31, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces That Topline Results of VTI-208 Fail to Achieve Primary or Secondary Endpoints of Improvement in Overall Survival Pre-Specified Exploratory Subset Analyses Suggest Efficacy Trends
August 21, 2015 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, Aug. 21, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Second Quarter 2015 Financial Results and Provides Corporate Update
July 30, 2015 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, July 30, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Second Quarter 2015 Financial Results Conference Call With Webcast Scheduled for Thursday, July 30, 2015
July 27, 2015 03:05 ET
|
Vital Therapies, Inc.
SAN DIEGO, July 27, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, will...
Vital Therapies Announces Appointment of Former Medivation Chief Commercial Officer Cheryl Cohen to Its Board of Directors
July 15, 2015 16:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, July 15, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Poster Presentation at International Liver Transplantation Society Meeting Today in Chicago
July 09, 2015 16:00 ET
|
Vital Therapies, Inc.
SAN DIEGO, July 9, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, announced...
Vital Therapies Announces First Quarter 2015 Financial Results and Provides a Corporate Update
May 12, 2015 16:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...
Vital Therapies Announces Poster Presentations From the Annual Meeting of the European Association for the Study of the Liver and Upcoming First Quarter Financial Results Conference Call With Webcast
April 27, 2015 08:01 ET
|
Vital Therapies, Inc.
SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of liver failure, today...